資源描述:
《子宮癌肉瘤26例臨床病理及預(yù)后影響因素分析》由會員上傳分享,免費在線閱讀,更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫。
1、萬方數(shù)據(jù)·520·臨床與實驗病理學(xué)雜志JClinExpPathol2007Oct;23(5)·論著·子宮癌肉瘤26例臨床病理及預(yù)后影響因素分析寧燕,周先榮,朱慧庭,王麗,曲玉清,朱勤,楊立峰摘要:目的探討子宮癌肉瘤的臨床病理特征及預(yù)后影響因素。方法收集1997年1月~2004年12月在復(fù)旦大學(xué)附屬婦產(chǎn)科醫(yī)院診治的26例子宮癌肉瘤患者的臨床病理資料,進行預(yù)后影響因素分析。結(jié)果26例患者平均年齡59.5歲,20例(76.9%)患者已絕經(jīng),主要癥狀是異常陰道流血。手術(shù)時,2l例(80.8%)患者未發(fā)現(xiàn)殘留病灶,其中l(wèi)o例(47.6%)術(shù)后出現(xiàn)復(fù)發(fā),平均緩解期為15個月,平均生存時間1
2、8個月。26例患者均獲得隨訪,總5年生存率26.5%,中位生存時間(334-7.33)個月,其中臨床分期I、Ⅱ、Ⅲ、Ⅳ期患者的5年生存率分別為79.1%、37.5%、13.3%、0,且I+Ⅱ期的5年生存率明顯高于Ⅲ+Ⅳ期(P=0.006)。單因素分析顯示:腫瘤大小、肌層浸潤深度、有無淋巴結(jié)轉(zhuǎn)移、有無殘留病灶以及臨床病理分期均與預(yù)后相關(guān)。多因素分析顯示:臨床病理分期是獨立的預(yù)后影響因素(P=0.035)。結(jié)論子宮癌肉瘤是侵襲性腫瘤,易發(fā)生子宮外播散、轉(zhuǎn)移。臨床病理分期是獨立的預(yù)后影響因素,提高早期檢出率,改進治療措施對提高子宮癌肉瘤的生存率有重要意義。關(guān)鍵詞:子宮腫瘤;癌肉瘤;病
3、理診斷;預(yù)后中圖分類號:R737.33文獻標(biāo)識碼:A文章編號:1001—7399(2007)05—0520—04Clinicalpathologyandprognosticfactorsofcarcinosarcomasofuterus:ananalysisof26casesNINGYan,ZHOUXian-rong,ZHUHui—ting,WANGLi,QUYu—qing,ZHUQin,YANGLi—feng(DepartmentofPathology,F(xiàn)udanUnive昭i@ObstetricandCynecolog幻Hospital,Shanghai200011,Chi
4、na)Abstract:PurposeToreviewtheelinicopathologicalfeaturesandtoidentifyprognosticfactorsinuterinecarcinosarcomas.MethodsTwenty—sixcasesofcarcinosarcomaoftheuteruswerestudiedretrospectivelyatFudanUniversityaffiliatedObstetricandGynecologicHospitalfromJanuary1997toDecember2004.ResultsTwenty-six
5、patientswithmedianageof59.5yearswereanalyzed,inwhichtwenty(76.9%)weremenopausal.AbnormalvaginalbleedingWaSthemostcommonsymptom.TherewereninepatientswithstageI,fivewithstageII,tenwithstageIIIandtwowithstageIVdisease.Therewasasignificantlydifferenceofsurvivaldistributionbe—tweenthelow-stagegro
6、up(stagesIand1I)andthehigh—stagegroup(stagesⅢand1V)(P=0.006).Atthecompletionofprimarysurgery,21(80.8%)patientshadnomacroscopicresidualtumors,Ten(47.6%)ofthesepatientshadrecurrenceofdisease,themediandisease—freetimewas15months,andmedianoverallsurvivalwas18months.Allpatientswerefollowedupwithm
7、edianoverallsurvivalof33months.a(chǎn)5-yearsurvivalrateof26.5%forallstages.Univariateanalysisshowedthatclinicopathologicalvariablesin·cludingtumorsize,depthofmyometrialinvasion,residualdisease,positivelymphnode,surgicalstagehaveasignificantassociationwi